Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B

References

• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1(Suppl1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361–1367. doi:10.1111/j.1440-1746.2011.06801.x
   PubMed Web of Science ®Google Scholar
• Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26(34):5576–5582. doi:10.1200/JCO.2008.16.1075
   PubMed Web of Science ®Google Scholar
• Yu MW, Lin CL, Liu CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153(4):1006–1017. doi:10.1053/j.gastro.2017.07.001
   PubMed Web of Science ®Google Scholar
• Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes. 2007;31(5):871–875.
   Web of Science ®Google Scholar
• Chan AW, Wong GL, Chan HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32(3):667–676. doi:10.1111/jgh.13536
   PubMed Web of Science ®Google Scholar
• Chen Y, Fan C, Chen Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: a prospective cohort and in vitro study. Oncotarget. 2017;8(35):58601–58610. doi:10.18632/oncotarget.17380
   PubMedGoogle Scholar
• Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539–548. doi:10.1002/hep.30857
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324. doi:10.1016/S2213-8587(18)30154-2
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA 3 and beyond. Gastroenterology. 2020;158(7):1865–1880. doi:10.1053/j.gastro.2020.01.053
   PubMed Web of Science ®Google Scholar
• Huang Z, Guo X, Zhang G, et al. Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects. Int J Biol Markers. 2019;34(2):117–122. doi:10.1177/1724600818812471
   PubMed Web of Science ®Google Scholar
• Shen JH, Li YL, Li D, et al. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res. 2015;56(1):167–175. doi:10.1194/jlr.M048777
   PubMed Web of Science ®Google Scholar
• Unalp-Arida A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U.S. population. Hepatology. 2020;71(3):820–834. doi:10.1002/hep.31032
   PubMed Web of Science ®Google Scholar
• Brouwer WP, van der Meer AJ, Boonstra A, et al. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term Clinical outcome in chronic hepatitis B patients. Liver Int. 2015;35(2):438–447. doi:10.1111/liv.12695
   PubMed Web of Science ®Google Scholar
• EASL-ALEH Clinical Practice. Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. doi:10.1016/j.jhep.2015.04.006
   PubMed Web of Science ®Google Scholar
• Wu CF, Yu MW, Lin CL, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis. 2008;29(1):106–112. doi:10.1093/carcin/bgm252
   PubMed Web of Science ®Google Scholar
• Sung FY, Jung CM, Wu CF, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology. 2009;137(5):1687–1697. doi:10.1053/j.gastro.2009.07.063
   PubMed Web of Science ®Google Scholar
• Cologne J, Preston DL, Imai K, et al. Conventional case-cohort design and analysis for studies of interaction. Int J Epidemiol. 2012;41(4):1174–1186. doi:10.1093/ije/dys102
   PubMed Web of Science ®Google Scholar
• van der Poorten D, Samer CF, Ramezani-Moghadam M, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57(6):2180–2188. doi:10.1002/hep.26072
   PubMed Web of Science ®Google Scholar
• Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12(5):438–446. doi:10.1007/s12072-018-9877-7
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–1465. doi:10.1038/ng.257
   PubMed Web of Science ®Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–1030. doi:10.1016/j.jhep.2016.12.022
   PubMed Web of Science ®Google Scholar
• Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59(3):550–556. doi:10.1016/j.jhep.2013.04.027
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–1155. doi:10.1016/j.jhep.2014.11.034
   PubMed Web of Science ®Google Scholar
• Bril F, Barb D, Lomonaco R, et al. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. J Hepatol. 2020;72(3):401–410. doi:10.1016/j.jhep.2019.09.018
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774–788. doi:10.1002/hep.23719
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. doi:10.1186/s12916-017-0806-8
   PubMed Web of Science ®Google Scholar
• Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol. 2008;19(3):295–300. doi:10.1097/MOL.0b013e3282ff5e55
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–1894. doi:10.1002/hep.24283
   PubMed Web of Science ®Google Scholar
• Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020;73(3):505–515. doi:10.1016/j.jhep.2020.04.003
   PubMed Web of Science ®Google Scholar
• Raksayot M, Chuaypen N, Khlaiphuengsin A, et al. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. J Gastroenterol. 2019;54(5):427–436. doi:10.1007/s00535-018-01533-x
   PubMed Web of Science ®Google Scholar
• Yang J, Trépo E, Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. Int J Cancer. 2019;144(3):533–544. doi:10.1002/ijc.31910
   PubMed Web of Science ®Google Scholar
• Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017;65(6):1875–1890. doi:10.1002/hep.29041
   PubMed Web of Science ®Google Scholar
• Carlsson B, Lindén D, Brolén G, et al. Review article: the emerging role of genetics in precision Medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305–1320. doi:10.1111/apt.15738
   PubMed Web of Science ®Google Scholar
• Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635–646. doi:10.1053/j.gastro.2018.10.027
   PubMed Web of Science ®Google Scholar
• Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. doi:10.1002/hep.24452
   PubMed Web of Science ®Google Scholar